Effect of Tight Blood Glucose Control Versus Conventional Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

被引:39
作者
Buehler, Anna Maria [1 ,2 ]
Cavalcanti, Alexandre Biasi [1 ]
Berwanger, Otavio [1 ]
Figueiro, Mabel [1 ]
Laranjeira, Ligia Nasi [1 ]
Zazula, Ana Denise [1 ]
Kioshi, Bruno [1 ]
Bugano, Diogo G. [1 ]
Santucci, Eliana [1 ]
Sbruzzi, Grazielle [1 ]
Guimaraes, Helio Penna [1 ]
Carvalho, Vitor Oliveira [1 ]
Bordin, Silvana Auxiliadora [1 ]
机构
[1] Hosp Coracao IEP HCor, Inst Ensino & Pesquisa, Sao Paulo, Brazil
[2] Univ Sao Paulo ICB I USP, Inst Ciencias Biomed, Sao Paulo, Brazil
关键词
Cardiovascular diseases; Glycemic control; Meta-analysis; Systematic review; Type 2 diabetes mellitus; CARDIOVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; SEVERE HYPOGLYCEMIA; GLYCEMIC CONTROL; ALL-CAUSE; PIOGLITAZONE; ROSIGLITAZONE; EVENTS; RISK; COMPLICATIONS;
D O I
10.1111/j.1755-5922.2011.00308.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tight control of blood glucose reduces cardiovascular events and total mortality is conflicting. To summarize clinical effects of tight versus conventional glucose control in patients with type 2 diabetes. We systematically searched MEDLINE, EMBASE, Cochrane Library, and ISI Web of Knowledge with no limits of language and time. Further trials were searched from the reference lists of identified studies. We included randomized controlled comparing different levels of blood glucose control intensity in type 2 diabetic patients. Two independent reviewers extracted data of eligible studies using standard case report forms. We investigated total mortality, cardiovascular and microvascular events, and hypoglycemia in patients with type 2 diabetes. We used random-effects models to obtain relative risks (RR) with 95% confidence intervals (CI). We included 6 trials involving 27,654 patients. There was no significant effect of tight blood glucose control on all-cause mortality (RR 1.03; 95% CI 0.901.17) or cardiovascular mortality (RR 1.04; 95% CI 0.831.29). Tight glucose control reduced the risk for nonfatal MI (RR 0.85; 95% CI 0.760.95), although had no effect on the incidence of nonfatal stroke (RR 1.02; 95% CI 0.881.17). For microvascular events, tight glucose control reduced the risk progression of retinopathy (RR 0.80; 95% CI 0.710.91), incidence of peripheral neuropathy (RR 0.94; 95% CI 0.890.99), and progression of nephropathy (RR 0.55; 95% CI 0.370.80), but had not significant effect on the incidence of nephropathy (RR 0.69; 95% CI 0.421.14). The risk of severe hypoglycemia increased with tight glucose control (RR 2.39; 95% CI 1.793.18). Tight blood glucose control reduces the risk for some macrovascular and microvascular events, without effect on all-cause mortality and cardiovascular mortality. Tight glucose control increases the risk of severe hypoglycemia.
引用
收藏
页码:147 / 160
页数:14
相关论文
共 46 条
[1]   VETERANS AFFAIRS COOPERATIVE STUDY ON GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES (VA CSDM) - RESULTS OF THE FEASIBILITY TRIAL [J].
ABRAIRA, C ;
COLWELL, JA ;
NUTTALL, FQ ;
SAWIN, CT ;
NAGEL, NJ ;
COMSTOCK, JP ;
EMANUELE, NV ;
LEVIN, SR ;
HENDERSON, W ;
LEE, HS .
DIABETES CARE, 1995, 18 (08) :1113-1123
[2]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[3]  
[Anonymous], NEW ENGL J MED
[4]  
[Anonymous], 2020, CAUSES DEATH
[5]   The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study [J].
Bonds, Denise E. ;
Miller, Michael E. ;
Bergenstal, Richard M. ;
Buse, John B. ;
Byington, Robert P. ;
Cutler, Jeff A. ;
Dudl, R. James ;
Ismail-Beigi, Faramarz ;
Kimel, Angela R. ;
Hoogwerf, Byron ;
Horowitz, Karen R. ;
Savage, Peter J. ;
Seaquist, Elizabeth R. ;
Simmons, Debra L. ;
Sivitz, William I. ;
Speril-Hillen, Joann M. ;
Sweeney, Mary Ellen .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 340 :137
[6]   Diabetic microvascular complications: possible targets for improved macrovascular outcomes [J].
D'Elia, John A. ;
Bayliss, George ;
Roshan, Bijan ;
Maski, Manish ;
Gleason, Ray E. ;
Weinrauch, Larry A. .
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2011, 4 :1-15
[7]   Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus [J].
Davidson, Michael ;
Meyer, Peter M. ;
Haffner, Steven ;
Feinstein, Steven ;
D'Agostino, Ralph ;
Kondos, George T. ;
Perez, Alfonso ;
Chen, Zhen ;
Mazzone, Theodore .
CIRCULATION, 2008, 117 (16) :2123-2130
[8]   Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia [J].
Deeg, Mark A. ;
Buse, John B. ;
Goldberg, Ronald B. ;
Kendall, David M. ;
Zagar, Anthony J. ;
Jacober, Scott J. ;
Khan, Mehmood A. ;
Perez, Alfonzo T. ;
Tan, Meng H. .
DIABETES CARE, 2007, 30 (10) :2458-2464
[9]   Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death [J].
Diamond, George A. ;
Bax, Leon ;
Kaul, Sanjay .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :578-581
[10]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289